Sequence of Treatments May Induce Clinical Response in Metastatic Renal Cell Carcinoma Patients

HOLLYWOOD, Fla., March 13, 2008 — Several recently approved agents offer promising treatment possibilities for patients with metastatic renal cell carcinoma (RCC) and the order in which these agents are administered may positively impact clinical response, according to a presentation given during the National Comprehensive Cancer Network (NCCN) 13th Annual Conference: Clinical Practice GuidelinesandQuality Cancer Care. Until recently, there were very few agents to treat RCC and those available ...
Source: National Comprehensive Cancer Network - Category: Cancer & Oncology Source Type: news

Related Links:

AbstractPancreatectomy might confer a survival benefit in patients with metastatic tumors of the pancreas (MTPs); however, the optimal treatment for MTP has not been established. We reviewed six patients with MTP undergoing pancreatectomy and discussed the clinical features, surgical treatment, and survival. The sites of primary cancer included renal cell carcinoma (RCC) (n = 5; 83.3%) and rectal cancer (n = 1; 16.7%). The median interval between the resection of the primary site and the development of MTP was 157 months (range, 16–180 months). Three (60.0%) of the five cases of ...
Source: Indian Journal of Surgical Oncology - Category: Cancer & Oncology Source Type: research
ConclusionProper differentiation of RCCs related to translocation of MiT family requires immunostaining for TFE3, especially in the case of younger patients, among which the prevalence of this genetic mutation is frequent.
Source: Journal of Pediatric Surgery Case Reports - Category: Surgery Source Type: research
Authors: Wei R, Ye X, Zhao Y, Jia N, Liu T, Lian W, Wei H, Zhang G, Song L Abstract MicroRNAs (miRs) have emerged as critical modulators of tumor initiation and progression in numerous types of human cancer, including clear cell renal cell carcinoma (ccRCC), which is the most common subtype of renal cell carcinoma. Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a newly characterized oncoprotein and its overexpression has been reported to promote cellular epithelial-mesenchymal transition and the tumor progression of ccRCC. The present study examined the effects of miR-218 on CIP2A expression in ccRCC cell...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
In conclusion, the present study suggested that GHET1 may be considered a therapeutic target for the treatment or prevention of RCC. PMID: 30867747 [PubMed]
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Authors: Xia L, Li S, Liu Y, Huang Y, Ni B, Wan L, Mei H, Li X, Cai Z, Li Z Abstract Neuron-derived neurotrophic factor (NDNF) is a glycosylated, disulfide-bonded secretory protein that contains a fibronectin type III domain. NDNF has been identified as a neurotrophic factor; however, its role in carcinogenesis has not yet been identified. To investigate the expression and role of NDNF in carcinogenesis, the expression of NDNF in human Renal cell carcinoma (RCC) cell lines and tissues was detected by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) and western blot analysis. Cell proliferation...
Source: Oncology Letters - Category: Cancer & Oncology Tags: Oncol Lett Source Type: research
Renal cell carcinoma (RCC) is one of the most frequent malignancies of the adults. Its incidence has been increasing steadily by 2–4% each year. Up to 30% of patients present with metastases at diagnosis. It is a highly vascularized cancer because of the hypoxia-induced factor stabilization as a consequence of von Hippel-Lindau inactivation. Hypoxia-induced factor accumulation leads to transactivation of molecules involved in angiogenesis including vascular endothelial growth factor (VEGF) and platelet-derived growth factor. Sunitinib is an oral tyrosine kinase inhibitor that interacts with several angiogenesis recep...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: CASE REPORTS Source Type: research
Among Swedish men, overweight or obesity during adolescence tied to higher risk for renal cell carcinoma
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Family Medicine, Nephrology, Nursing, Oncology, Pediatrics, Urology, Journal, Source Type: news
Dr. Julie Brahmer, Johns Hopkins University, discusses the use of biomarker testing and mutational burden to select patients for specific immunotherapies in lung cancer, renal cell carcinoma and melan... Author: cancergrace Added: 03/15/2019
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts
FRIDAY, March 15, 2019 -- Overweight and obesity in adolescence is associated with an increased risk for developing renal cell carcinoma (RCC) later in life, according to a study published online Feb. 20 in the International Journal of Cancer. Anna...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news
Abstract Extracellular vesicles (EVs) are important mediators of intercellular communication in cancer and in normal tissues. EVs transfer biologically active molecules from the cell of origin to recipient cells. This review summarizes the studies on EVs derived from renal cell carcinoma and from a subpopulation of CD105-positive renal cancer stem cells. While EVs from renal cell carcinoma show mild biological activity, EVs from renal cancer stem cells enhance tumor angiogenesis and metastasis formation. The effect is probably due to the transfer of proangiogenic RNA cargo to endothelial cells, which acquire an ac...
Source: Molecular Medicine - Category: Molecular Biology Authors: Tags: Exp Mol Med Source Type: research
More News: Cancer | Cancer & Oncology | Carcinoma | Conferences | Kidney Cancer | Renal Cell Carcinoma